Clinical relevance of tumour-associated macrophages
MJ Pittet, O Michielin, D Migliorini - Nature reviews Clinical oncology, 2022 - nature.com
In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
H Zhang, L Liu, J Liu, P Dang, S Hu, W Yuan, Z Sun… - Molecular Cancer, 2023 - Springer
In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …
Multifaceted carbonized metal–organic frameworks synergize with immune checkpoint inhibitors for precision and augmented cuproptosis cancer therapy
The discovery of cuproptosis, a copper-dependent mechanism of programmed cell death,
has provided a way for cancer treatment. However, cuproptosis has inherent limitations …
has provided a way for cancer treatment. However, cuproptosis has inherent limitations …
Tumor abnormality-oriented nanomedicine design
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Targeting macrophages in cancer immunotherapy
Z Duan, Y Luo - Signal transduction and targeted therapy, 2021 - nature.com
Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …
Targeting tumor-associated macrophages to synergize tumor immunotherapy
X Xiang, J Wang, D Lu, X Xu - Signal transduction and targeted therapy, 2021 - nature.com
The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …
immunotherapies have raised hope for a successful control of these advanced diseases, but …
Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Humoral immune responses are characterized by complex mixtures of polyclonal antibody
species varying in their isotype, target epitope specificity and affinity. Posttranslational …
species varying in their isotype, target epitope specificity and affinity. Posttranslational …
Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression
Y Pu, Q Ji - Frontiers in immunology, 2022 - frontiersin.org
Anti-programmed cell death 1 (PD-1) or anti-PD-ligand (L) 1 drugs, as classic immune
checkpoint inhibitors, are considered promising treatment strategies for tumors. In clinical …
checkpoint inhibitors, are considered promising treatment strategies for tumors. In clinical …